References
Vojtisek R, Baxa J, Kovarova P, Almortaza A, Hosek P, Sukovska E et al (2021) Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. Strahlenther Onkol 197(6):494–504. https://doi.org/10.1007/s00066-020-01740-7
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G,Maiman MA et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15):1144–1153. https://doi.org/10.1056/NEJM199904153401502
Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE (2004) Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-risk stage IIB cervical carcinoma. Int J Clin Oncol 9(2):120–124. https://doi.org/10.1007/s10147-003-0378-9
Onal C, Reyhan M, Guler OC, Yapar AF (2014) Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging 41(7):1336–1342. https://doi.org/10.1007/s00259-014-2719-5
Olawaiye AB, Baker TP, Washington MK, Mutch DG (2021) The new (Version 9) American Joint Committee on cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. https://doi.org/10.3322/caac.21663
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135. https://doi.org/10.1002/ijgo.12749
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
C. Onal, G. Yavas, and C. Yavas declare that they have no competing interests.
Additional information
This comment refers to the article available online at https://doi.org/10.1007/s00066-020-01740-7.
C. Onal, G. Yavas, and C. Yavas contributed equally.
Rights and permissions
About this article
Cite this article
Onal, C., Yavas, G. & Yavas, C. Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. In regard to Vojtíšek et al.. Strahlenther Onkol 197, 935–936 (2021). https://doi.org/10.1007/s00066-021-01819-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-021-01819-9